Literature DB >> 26424826

A predictable but life-threatening complication of hydroxyurea in a patient with sickle cell anaemia: an experience learned from a Jehovah's Witness.

Aung Myint Tun1, Ei Ei Naing2, Nay Min Tun3, Elizabeth Guevara3.   

Abstract

It is well known that hydroxyurea can cause pancytopaenia secondary to bone marrow suppression, which is reversible with short-term discontinuation of the therapy. However, it is important to note that bone marrow suppressive effects caused by hydroxyurea could be easily potentiated in patients with sickle cell anaemia complicated by chronic kidney disease (CKD). We present a case of a Jehovah's Witness with sickle cell anaemia, who developed severe bone marrow suppression due to the combined effects of hydroxyurea and CKD, resulting in a prolonged recovery period after discontinuation of hydroxyurea. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26424826      PMCID: PMC4593259          DOI: 10.1136/bcr-2015-211785

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  Hydroxyurea for the treatment of sickle cell anemia.

Authors:  Orah S Platt
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

2.  A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.

Authors:  G I Rodriguez; J G Kuhn; G R Weiss; S G Hilsenbeck; J R Eckardt; A Thurman; D A Rinaldi; S Hodges; D D Von Hoff; E K Rowinsky
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

3.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Authors:  Martin H Steinberg; Franca Barton; Oswaldo Castro; Charles H Pegelow; Samir K Ballas; Abdullah Kutlar; Eugene Orringer; Rita Bellevue; Nancy Olivieri; James Eckman; Mala Varma; Gloria Ramirez; Brian Adler; Wally Smith; Timothy Carlos; Kenneth Ataga; Laura DeCastro; Carolyn Bigelow; Yogen Saunthararajah; Margaret Telfer; Elliott Vichinsky; Susan Claster; Susan Shurin; Kenneth Bridges; Myron Waclawiw; Duane Bonds; Michael Terrin
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

4.  Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia.

Authors:  Ofelia Alvarez; Scott T Miller; Winfred C Wang; Zhaoyu Luo; M Beth McCarville; George J Schwartz; Bruce Thompson; Thomas Howard; Rathi V Iyer; Sohail R Rana; Zora R Rogers; Sharada A Sarnaik; Courtney D Thornburg; Russell E Ware
Journal:  Pediatr Blood Cancer       Date:  2012-01-31       Impact factor: 3.167

5.  Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure.

Authors:  Patrick T McGann; Thad A Howard; Jonathan M Flanagan; Jill M Lahti; Russell E Ware
Journal:  Br J Haematol       Date:  2011-05-04       Impact factor: 6.998

6.  Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients.

Authors:  Darleen R Powars; Linda S Chan; Alan Hiti; Emily Ramicone; Cage Johnson
Journal:  Medicine (Baltimore)       Date:  2005-11       Impact factor: 1.889

Review 7.  Advances in the use of hydroxyurea.

Authors:  Russell E Ware; Banu Aygun
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

8.  Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent.

Authors:  Geraldo B Silva Junior; Ana Patrícia F Vieira; Amanda X Couto Bem; Marília P Alves; Gdayllon C Meneses; Alice M C Martins; Sonia M H A Araújo; Alexandre V Libório; Elizabeth F Daher
Journal:  Int J Clin Pharm       Date:  2014-06-17

Review 9.  Nitric oxide production from hydroxyurea.

Authors:  S Bruce King
Journal:  Free Radic Biol Med       Date:  2004-09-15       Impact factor: 7.376

Review 10.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.